Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4482 - Epigenomic landscape of Breast Cancer in Very Young Women

Date

11 Sep 2017

Session

Poster display session

Presenters

Sara Oltra Sanchis

Citation

Annals of Oncology (2017) 28 (suppl_5): v1-v21. 10.1093/annonc/mdx361

Authors

S. Oltra Sanchis1, M.P. Chilet1, M. Martinez2, K. Flower3, E. Alonso2, O. Burgues4, A. Lluch5, J. Flanagan3, G. Ribas1

Author affiliations

  • 1 Oncología Médica, INCLIVA Instituto de investigación sanitaria, 46010 - Valencia/ES
  • 2 Oncología Médica, Hospital Clínico Universitario de Valencia, 46010 - Valencia/ES
  • 3 Department Of Surgery And Cancer, Imperial College London, London/GB
  • 4 Pathological Anatomy, Hospital Clínico Universitario de Valencia, 46010 - Valencia/ES
  • 5 Medical Oncology  , Hospital Clinico Universitario de Valencia, 46010 - Valencia/ES
More

Resources

Abstract 4482

Background

Although less frequent than in older women, breast cancer in very young women (BCVY) (≤35 years old) presents more aggressive and complex biological features. Epigenetic modifications such as miRNA regulation or DNA methylation are reported to play an important role in the onset and progression of cancer. The aim of this work is to identify the epigenetics mechanisms characteristics of BCVY that may be conferring more aggressive features to this group of patients.

Methods

We analysed methylation (Infinium MethylationEPIC BeadChip) from 26 BCVY and 15 samples from women >45 years old. Methylation differences were assessed using Wilcoxon rank sum test. We selected from The Cancer Genome Atlas (TCGA) those genes regulated by significantly different methylated sites and their expression was analysed. MiRNA expression data from TCGA, METABRIC and data previously published from our group was evaluated in a meta-analysis. We then selected those target genes which expression was more affected by miRNA deregulation. Pathway enrichment analysis was performed with most relevant genes from the epigenetic study by Enrichr.

Results

We detected a global hypomethylation profile in BCVY samples and hypermetilation of 502 specific CpG sites exclusive of this group of age. Hypomethylated CpG sites were regulating genes mainly involve in neuronal processes, extracellular matrix and cell communication. Whereas specific hypermethylation was located in genes related to immune system, NOTCH signalling, vesicular trafficking, DNA repair and senescence. MiRNA expression meta-analysis revealed a profile of 22 miRNAs significantly deregulated in BCVY. Pathway enrichment analysis of most affected target genes showed an involvement in neural processes, glucose metabolism, vesicular trafficking, DNA repair, histone and chromatin related proteins, apoptosis, cell cycle, response to DNA damage and senescence.

Conclusions

Our work highlights the presence of epigenomic profile distinctive of BCVY. Both methylation and miRNAs studies points to deregulation of pathways related to neural processes, vesicular trafficking, DNA repair and senescence. All these processes may lead to cancer development and progression, thus genes in these pathways may be potential candidates for further studies.

Clinical trial identification

Legal entity responsible for the study

INCLIVA Research Institute

Funding

None

Disclosure

S. Sanchis: Funded on a FPU predoctoral Fellowship (FPU13/04976) from MINECO, Spanish Government.

rn

G. Ribas: Funded on a Miquel Servet II contract (CPII14-00013) from CarlosIII Health Institute.

rn

M.P. Chilet: Funded by private Patients Fundation LeCado. CIBERONC is an initiative of the Carlos III Health Institute.All other authors have declared no conflicts of interest.

Disclosure

S. Sanchis: Funded on a FPU predoctoral Fellowship (FPU13/04976) from MINECO, Spanish Government.

\r\n

G. Ribas: Funded on a Miquel Servet II contract (CPII14-00013) from CarlosIII Health Institute.

\r\n

M.P. Chilet: Funded by private Patients Fundation LeCado. CIBERONC is an initiative of the Carlos III Health Institute.All other authors have declared no conflicts of interest.

Disclosure

S. Sanchis: Funded on a FPU predoctoral Fellowship (FPU13/04976) from MINECO, Spanish Government.

G. Ribas: Funded on a Miquel Servet II contract (CPII14-00013) from CarlosIII Health Institute.

M.P. Chilet: Funded by private Patients Fundation LeCado. CIBERONC is an initiative of the Carlos III Health Institute.All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.